Michael Amoroso
Chief Executive Officer chez PRECISION BIOSCIENCES, INC.
Fortune : 735 212 $ au 31/03/2024
Profil
Michael Amoroso is currently the President, Chief Executive Officer & Director at Precision BioSciences, Inc. He is also the Chairman at Abeona Therapeutics, Inc. Previously, he worked as the SVP & Head-Cell Therapy Worldwide Commercial at Kite Pharma, Inc. Michael completed his undergraduate degree at Rider University and holds an MBA from The Leonard N Stern School of Business.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 01/03/2024 | 79 187 ( 0,29% ) | 574 106 $ | 31/03/2024 | |
| 18/04/2024 | 11 881 ( 0,18% ) | 161 106 $ | 31/03/2024 |
Postes actifs de Michael Amoroso
| Sociétés | Poste | Début |
|---|---|---|
| ABEONA THERAPEUTICS INC. | Chairman | 14/10/2021 |
| PRECISION BIOSCIENCES, INC. | Chief Executive Officer | 15/10/2021 |
Anciens postes connus de Michael Amoroso
| Sociétés | Poste | Fin |
|---|---|---|
| KITE PHARMA INC | Corporate Officer/Principal | 01/01/2020 |
Formation de Michael Amoroso
| Rider University | Undergraduate Degree |
| The Leonard N Stern School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ABEONA THERAPEUTICS INC. | Health Technology |
| PRECISION BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Kite Pharma, Inc.
 Kite Pharma, Inc. BiotechnologyHealth Technology Kite Pharma, Inc. engages in the the development and commercialization of cancer immunotherapy products. Its products include chimeric antigen receptor (CAR) and T cell receptor (TCR), which address both hematological and solid cancers. The company was founded by Arie S. Belldegrun, James S. Economou, and Joshua A. Kazam on 2009 and is headquartered in Santa Monica, CA. | Health Technology |
